Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 7/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.52 |
| ▸ | YAP1 | P46937 | 1/20 | 0.47 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.47 |
| ▸ | GSTM2 | P28161 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.45 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29919848 | 1.00 | BCL2 (0.52) | BCL2MCL1KLK5YAP1GSTP1 | |
| SCHEMBL29162420 | 0.93 | ACE (0.54) | BCL2MCL1PPARAACECTSS | |
| SCHEMBL23574509 | 0.87 | GSTP1 (0.52) | BCL2MCL1KLK5GSTP1GSTM2 | |
| SCHEMBL4107063 | 0.87 | KLK5 (0.58) | BCL2KLK5YAP1PPARAACE | |
| SCHEMBL23574510 | 0.87 | GSTP1 (0.52) | BCL2MCL1KLK5GSTP1GSTM2 | |
| SCHEMBL4107015 | 0.87 | KLK5 (0.58) | BCL2KLK5YAP1PPARAACE | |
| SCHEMBL3574819 | 0.87 | GSTP1 (0.48) | BCL2MCL1KLK5GSTP1GSTM2 | |
| SCHEMBL3574824 | 0.87 | GSTP1 (0.48) | BCL2MCL1KLK5GSTP1GSTM2 | |
| SCHEMBL29919587 | 0.86 | BCL2 (0.47) | BCL2MCL1PPARAACEITGA4 | |
| SCHEMBL16227984 | 0.85 | KLK5 (0.56) | BCL2KLK5YAP1PPARAACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492780-B1 | 5-SUBSTITUTED 1,1-DIOXO-¬1,2,5 THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS | NOVARTIS AG (CH) | 2011-11-23 | — | — | EP | disclosed |
| EP-2341049-A1 | 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as PTPASE 1B inhibitors | Novartis AG (CH) | 2011-07-06 | — | — | EP | disclosed |
| US-20080139576-A1 | 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives | NOVARTIS AG (CH) | 2008-06-12 | — | — | US | disclosed |
| US-7291635-B2 | 5-substituted 1,1-dioxo-1,2,5,-thiadiazolidin-3-one derivatives | NOVARTIS AG (CH) | 2007-11-06 | — | — | US | disclosed |
| US-20050090502-A1 | Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents | NOVARTIS AG (CH) | 2005-04-28 | — | — | US | disclosed |
| EP-1492780-A1 | 5-SUBSTITUTED 1,1-DIOXO-[1,2,5]THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS | Novartis AG (CH) | 2005-01-05 | — | — | EP | disclosed |
| US-20040023974-A1 | Cyclic sulfamide derivatives and methods of use | COPPOLA GARY MARK | 2004-02-05 | — | — | US | disclosed |
| WO-2003082841-A1 | 5-SUBSTITUTED 1,1-DIOXO-`1,2,5!THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS | NOVARTIS AG (CH) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139576-A1 | 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives | PTPRS, PTPRJ, IRS1 | BCL2 2428/4885MCL1 2837/4885KLK5 2702/4885 |
| US-20050090502-A1 | Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents | PTPRS, PTPMT1, PTPN1 | BCL2 948/4885MCL1 1905/4885KLK5 3958/4885 |
| US-20040023974-A1 | Cyclic sulfamide derivatives and methods of use | PTPRS, PTPA, PTPMT1 | BCL2 1776/4885MCL1 2482/4885KLK5 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.